Stockscreener 앱 받기
0.7629
3.43%
-0.0271
시간 외 거래:
.76
-0.0029
-0.38%
전일 마감가:
$0.79
열려 있는:
$0.787
하루 거래량:
29,601
Relative Volume:
0.14
시가총액:
$1.62M
수익:
$4.70M
순이익/손실:
$-4.99M
주가수익비율:
-0.1188
EPS:
-6.42
순현금흐름:
$-5.29M
1주 성능:
-0.99%
1개월 성능:
+9.30%
6개월 성능:
-46.65%
1년 성능:
-79.34%
1일 변동 폭
$0.7629
$0.787
1주일 범위
$0.761
$0.8399
52주 변동 폭
$0.4519
$7.20
Salarius Pharmaceuticals Inc Stock (SLRX) Company Profile
명칭
Salarius Pharmaceuticals Inc
전화
346-772-0346
주소
2450 HOLCOMBE BLVD, HOUSTON
SLRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLRX
Salarius Pharmaceuticals Inc
|
0.7629 | 1.64M | 4.70M | -4.99M | -5.29M | -6.42 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Salarius Pharmaceuticals Inc Stock (SLRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-04-27 | 개시 | Ladenburg Thalmann | Buy |
Salarius Pharmaceuticals Inc 주식(SLRX)의 최신 뉴스
Liposarcoma Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 15+ Companies and 20+ Therapies | DelveInsight - GlobeNewswire Inc.
Salarius: Q1 Earnings Snapshot - New Haven Register
Salarius Pharmaceuticals (NASDAQ:SLRX) Trading Up 2.1% – Here’s Why - Defense World
Financial Analysis: Hepion Pharmaceuticals (NASDAQ:HEPA) versus Salarius Pharmaceuticals (NASDAQ:SLRX) - Defense World
Closing Figures Unveiled: Salarius Pharmaceuticals Inc (SLRX) Drop -26.34, Closes at 0.60 - DWinneX
Salarius Pharmaceuticals faces Nasdaq delisting over rule breaches By Investing.com - Investing.com Canada
Salarius Pharmaceuticals faces Nasdaq delisting over rule breaches - Investing.com
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Robert S. Langer To Scientific Advisory Board - citybiz
Decoy Therapeutics to Welcome MIT's Robert Langer to Advisory Board Post-Merger with Salarius (SLRX) | SLRX Stock News - GuruFocus
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board - The Manila Times
Moderna Co-Founder and MIT Legend Strengthens Decoy Therapeutics Drug Development Team - Stock Titan
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
SLRX stock touches 52-week low at $0.7 amid sharp annual decline - Investing.com Canada
SLRX stock touches 52-week low at $0.7 amid sharp annual decline By Investing.com - Investing.com South Africa
Contrasting Salarius Pharmaceuticals (NASDAQ:SLRX) & ASLAN Pharmaceuticals (NASDAQ:ASLN) - Defense World
Salarius Amends Merger Terms, Faces Nasdaq Compliance Issue By Investing.com - Investing.com India
Salarius Amends Merger Terms, Faces Nasdaq Compliance Issue - Investing.com
Decoy Therapeutics’ antiviral candidates show broad activity against multiple viruses - BioWorld MedTech
SLRX stock touches 52-week low at $0.83 amid market challenges By Investing.com - Investing.com South Africa
SLRX stock touches 52-week low at $0.83 amid market challenges - Investing.com Australia
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces Its Novel Inhibitors Show Promising In Silico Activity Against Measles And Related Viruses - MarketScreener
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces its Novel Inhibitors Show Promising In Silico Activity Against Measles and Related Viruses - GlobeNewswire
Revolutionary AI Platform Discovers Multi-Target Antiviral in Just 5 Days - Stock Titan
Salarius Pharmaceuticals Advances Merger with Decoy Therapeutics to Enhance Development of Innovative Cancer and Viral Therapeutics - Nasdaq
Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update - GlobeNewswire
Salarius Pharmaceuticals Inc. (SLRX) reports earnings - Quartz
Salarius Pharmaceuticals, Inc. SEC 10-K Report - TradingView
Apraxia Treatment Market Size in 7MM is expected to grow at - openPR.com
Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Short Interest Update - Defense World
SLRX stock touches 52-week low at $0.9 amid market challenges - Investing.com
SLRX stock touches 52-week low at $0.9 amid market challenges By Investing.com - Investing.com South Africa
Salarius Pharmaceuticals announces registered share offering By Investing.com - Investing.com South Africa
Salarius Pharmaceuticals announces registered share offering - Investing.com
SLRX stock touches 52-week low at $1.22 amid market challenges - Investing.com Australia
SLRX stock touches 52-week low at $1.22 amid market challenges By Investing.com - Investing.com South Africa
Salarius Pharmaceuticals Inc to Host Earnings Call - ACCESS Newswire
Salarius Pharmaceuticals (NASDAQ:SLRX) Shares Up 0.5% – Still a Buy? - Defense World
What Recent Market Trends Mean for Salarius Pharmaceuticals Inc’s (SLRX) Stock - The News Heater
Salarius Pharmaceuticals Inc (SLRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
3.74%
자본화:
|
볼륨(24시간):